一名接受口服芬维A胺治疗的4期神经母细胞瘤患者发生朗格汉斯细胞组织细胞增多症。
Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide.
作者信息
Rayburg Melissa, Towbin Alexander, Yin Hong, Maugans Todd, Maurer Barry, Nagarajan Rajaram, Weiss Brian
机构信息
Division of Hematology/Oncology, Cincinnati Children's Hospital, Cincinnati, Ohio 45249, USA.
出版信息
Pediatr Blood Cancer. 2009 Dec;53(6):1111-3. doi: 10.1002/pbc.22200.
Langerhans cell histiocytosis (LCH) has previously been reported in association with other malignancies. The pathogenesis of LCH and its relationship to other malignancies is poorly understood. We present a novel case of a child who developed an LCH bone lesion while receiving a Phase I protocol therapy with oral fenretinide/Lym-X-Sorb (4-HPR/LXS) powder for neuroblastoma.
朗格汉斯细胞组织细胞增多症（LCH）此前已有与其他恶性肿瘤相关的报道。LCH的发病机制及其与其他恶性肿瘤的关系尚不清楚。我们报告了一例新病例，一名儿童在接受口服维甲酸/ Lym-X-Sorb（4-HPR/LXS）粉末治疗神经母细胞瘤的I期方案治疗时出现了LCH骨病变。
Zotero 插件